Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 7/20 | 0.53 |
| ▸ | EHMT2 | Q96KQ7 | 13/20 | 0.48 |
| ▸ | KDM1A | O60341 | 6/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 6/20 | 0.47 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.46 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.46 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427825 | 0.91 | NSD2 (0.63) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL1428356 | 0.90 | NSD2 (0.54) | NSD2EHMT2KDM1ARCOR1EZH2 | |
| SCHEMBL1428353 | 0.86 | NSD2 (0.56) | NSD2EHMT2KDM1ARCOR1 | |
| SCHEMBL1427624 | 0.86 | NSD2 (0.56) | NSD2EHMT2KDM1ARCOR1 | |
| SCHEMBL1427625 | 0.86 | NSD2 (0.56) | NSD2EHMT2KDM1ARCOR1 | |
| SCHEMBL1427833 | 0.85 | NSD2 (0.57) | NSD2EHMT2KDM1ARCOR1DNMT3A | |
| SCHEMBL9911794 | 0.84 | EHMT2 (0.66) | EHMT2KDM1ARCOR1EZH2EHMT1 | |
| SCHEMBL1427572 | 0.83 | NSD2 (0.56) | NSD2EHMT2KDM1ARCOR1EZH2 | |
| SCHEMBL4202122 | 0.82 | EHMT2 (0.59) | NSD2EHMT2KDM1ARCOR1EZH2 | |
| SCHEMBL1427537 | 0.81 | NSD2 (0.43) | NSD2EHMT2KDM1ARCOR1EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193203-B2 | Bicyclic compounds having activity at the CXCR4 receptor | ALLERGAN, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-102105463-A | Bicyclic compounds active on the CXCR4 receptor | ALLERGAN INC | 2011-06-22 | — | — | CN | disclosed |
| EP-2300456-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | Allergan, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009143058-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143058-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | ALLERGAN, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312305-A1 | BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR | CXCR4, CXCR2, CXCL12 | NSD2 4654/4885EHMT2 4669/4885KDM1A 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.